A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Protocol No
IIT-RUNAAS-TILDRAKIZUMAB-AGVHD
Principal Investigator
Lyndsey Runaas
Phase
II
Summary
In this study we want to find out if giving Tildrakizumab (100 mg) as a subcutaneous injection on Day -1 in combination with the standard GVHD prophylaxis; Tacrolimus and Methotrexate will help prevent acute and chronic GVHD
Description
Tidrakizumab for Prevention of Acute Graft-Versus-Host Disease
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: